Tenofovir Disoproxil

BreastfeedingPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Acyclovir, Adefovir, Atazanavir, Cidofovir, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Darunavir, Didanosine, Ganciclovir, High-fat foods, Indinavir, Ledipasvir & Sofosbuvir, Lopinavir, Protease inhibitors, Ritonavir, Telaprevir, Tipranavir, Trospium, Valacyclovir, Valganciclovir

PREGNANCY CATEGORY: B

Atripla is tenofovir disoproxil, efavirenz and emtricitabine; Complera is tenofovir disoproxil, emtricitabine and rilpivirine; Truvada is tenofovir disoproxil and emtricitabine.

See also separate profile for tenofovir disoproxil in combination with cobicistat, elvitegravir and emtricitabine.

LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS

See full prescribing information for complete boxed warning.

Our database has 69 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
RENAL
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tenofovir in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 03/01/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top